Objective
All of modern medicine is dependent on advances in chemistry and the healthcare goalposts have moved as the century has progressed. The pressing need to shorten cycle times and reduce the costs of drug discovery has led pharma and the clinicians that guide them to use scanning techniques such as positron emission tomography (PET), enabling them to increase disease understanding, study target engagement with therapeutics and improve decision making, so that only the best candidate molecules progress to the later stages of drug development. Overcoming these challenges requires multidisciplinary knowledge, and can be facilitated through stronger links between academia and Pharma. Chemical entities substituted with fluorine or fluorine-containing groups are frequently used to design drugs with improved pharmacological and pharmacokinetic profiles that provide important benefits over existing therapies, such as superior safety, efficacy, dosing, and patient compliance. Furthermore, 18F is often selected as the preferred positron-emitting isotope for the labeling of PET tracers due to its advantageous properties. The scientific objective of FLUDD is to develop novel late stage fluorination chemistry to populate the chemical and radiochemical space available for drug discovery with a focus on novel fluorine-containing fragments, molecules and biomolecules that are not directly accessible from commercial sources or the scientific literature. These novel methodologies will be applied to drugs and diagnostics discovery using both small molecules and proteins. The educational objective is to train the next generation of doctoral scientists in the practice of chemical synthesis and radiochemical methods with an in-depth appreciation of their applications in medicine. FLUDD objectives will be met with a novel Oxford-Janssen Alliance augmented with leading partners from academia, industry and the clinic.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences health sciences infectious diseases
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- medical and health sciences medical biotechnology tissue engineering bioartificial liver
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN-EID - European Industrial Doctorates
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
OX1 2JD Oxford
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.